(Albany, United States) As per DelveInsight’s assessment, globally, the Systemic Lupus Erythematosus pipeline constitutes 55+ key companies continuously working towards developing 60+ Systemic Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Systemic Lupus Erythematosus Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Systemic Lupus Erythematosus clinical trials studies, Systemic Lupus Erythematosus NDA approvals (if any), and product development activities comprising the technology, Systemic Lupus Erythematosus collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Systemic Lupus Erythematosus pipeline treatment landscape of the report, click here @ Systemic Lupus Erythematosus Pipeline Outlook
Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report
- DelveInsight’s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline treatment therapies.
- The leading Systemic Lupus Erythematosus Companies working in the market include Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Resolve, Provention Bio, Pfizer, Novartis Pharmaceuticals, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others
- Promising Systemic Lupus Erythematosus Pipeline Therapies in the various stages of development include Anifrolumab, Medi-546, LY3471851, Baricitinib, MEDI-545 600, Sifalimumab, Belimumab 10mg/kg, Ianalumab, BMS-986165, and others.
- On January 2023, AstraZeneca annoucned a study of phase 3 clinical trials for Anifrolumab. The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
- On June 2023, AstraZeneca announced a study of phase 3 clinical trials for Medi-546. The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy.
- On April 2023, Eli Lilly and Company announced a study of phase 2 clinical trials for LY3471851. The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Systemic Lupus Erythematosus Overview
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. Several immunopathogenic pathways play a role in the development of SLE.
To explore more information on the latest breakthroughs in the Systemic Lupus Erythematosus Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight
Systemic Lupus Erythematosus Emerging Drugs Profile
- Obinutuzumab (Gazyva): Roche
- Dapirolizumab pegol: UCB
- BIIB059: Biogen
- PRV 3279: Provention Bio
- ABBV-599: AbbVie
Systemic Lupus Erythematosus Pipeline Therapeutics Assessment
There are approx. 55+ Systemic Lupus Erythematosus companies which are developing the therapies for Systemic Lupus Erythematosus. The Systemic Lupus Erythematosus companies which have their Systemic Lupus Erythematosus drug candidates in the most advanced stage, i.e. Phase III include, Roche.
Request a sample and discover the recent advances in Systemic Lupus Erythematosus Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight
Systemic Lupus Erythematosus Drugs and Companies
- Anifrolumab: AstraZeneca
- Medi-546: Iqvia Pty Ltd
- LY3471851: Eli Lilly and Company
- Baricitinib: Incyte Corporation
Systemic Lupus Erythematosus Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Systemic Lupus Erythematosus Therapeutics Market include-
Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Resolve, Provention Bio, Pfizer, Novartis Pharmaceuticals, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others
Dive deep into rich insights for drugs for Systemic Lupus Erythematosus Pipeline, click here for Systemic Lupus Erythematosus Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight
Scope of the Systemic Lupus Erythematosus Pipeline Report
- Coverage- Global
- Systemic Lupus Erythematosus Companies- Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Resolve, Provention Bio, Pfizer, Novartis Pharmaceuticals, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others
- Systemic Lupus Erythematosus Pipeline Therapies- Anifrolumab, Medi-546, LY3471851, Baricitinib, MEDI-545 600, Sifalimumab, Belimumab 10mg/kg, Ianalumab, BMS-986165, and others
- Systemic Lupus Erythematosus Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Systemic Lupus Erythematosus Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Systemic Lupus Erythematosus: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Systemic Lupus Erythematosus – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Obinutuzumab: Roche
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- PRV 3279: Provention Bio
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- E6742: Eisai
- Drug profiles in the detailed report…..
- Inactive Products
- Systemic Lupus Erythematosus – Collaborations Assessment- Licensing / Partnering / Funding
- Systemic Lupus Erythematosus – Unmet Needs
- Systemic Lupus Erythematosus – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services